HGF and Signaling Pathways in Hepatic Tissue Assembly

HGF 和肝组织组装中的信号通路

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT This is a revised renewal application for a grant, now in its 5th year, aiming to understand the role of HGF and signaling pathways in hepatic tissue assembly. Our recent studies have demonstrated that HGF and its receptor Met, as well as EGF receptor and the EGFR associated ligands) constitute the only two receptor tyrosine kinases capable of delivering a mitogenic signal to hepatocytes (in serum-free media and when administered to the whole animal, rat or mouse). We have also showed that HGF/Met and EGFR are the only two signaling systems capable of promoting transdifferentiation of hepatocytes to biliary epithelial cells in culture. These unique effects of HGF/Met and EGFR are highly significant. Many other receptor tyrosine kinases are expressed in hepatocytes and their ligands are capable of activating the cognate receptor, yet mitogenic signals are limited to HGF/Met and EGFR. We have recently applied short term knock down (KD) of either HGF/Met or EGFR by ShRNA and demonstrated that both have inhibitory effects on liver regeneration, that the one signal cannot compensate totally for the other, and that the effects are different in scope and complexity. KD of EGFR was followed by compensatory increases in other members of the ErbB family and upregulation of MET. In each instance, there was significant but not lethal activation of pro-apoptotic pathways. We further extend these studies in rats and performed a double KD of both HGF/Met and EGFR followed by partial hepatectomy (PHx). The result was complete liver failure, with massive apoptosis and necrosis of most hepatocytes and collapse of the hepatic parenchyma. This effect was not seen when double KD was performed without PHx. The proposed study will aim to determine the signals that lead to liver failure under the hypothesis that many cytokines involved in liver regeneration (e.g. TNF and TGFb1) can also function as agents that bring hepatocyte death and liver failure when the mitogenic signals of both EGFR and MET fail to function. In addition to the experimental studies, we will also analyze expression and status of activation of the above receptors as well cytokines capable of inducing hepatocyte death and liver failure in human liver material obtained from cases of fulminant hepatic necrosis.. Finally we will assess the importance of the compensatory mechanisms emerging after KD of EGFR and determine whether abrogation of these mechanisms is capable to also lead to liver failure by itself. The combination of these studies may allow us to understand the mechanisms that lead to massive hepatic necrosis as an aberrant dis-coordination of the early signals involved in liver regeneration and allow design of therapeutic interventions for prevention of massive hepatic necrosis based on rational mechanistic schemes.
项目摘要/摘要 这是授予赠款的修订后的续签申请,目前是第5年,旨在了解HGF和 肝组织组装中的信号通路。我们最近的研究表明,HGF及其 受体MET,以及EGF受体和EGFR相关的配体)仅构成两个受体 能够向肝细胞传递有丝分裂信号的酪氨酸激酶(在无血清培养基和何时 给整个动物,大鼠或小鼠)。我们还表明,HGF/MET和EGFR是唯一的 两个信号系统,能够促进肝细胞转分化向胆道上皮细胞 文化。 HGF/MET和EGFR的这些独特影响非常重要。许多其他受体酪氨酸 激酶在肝细胞中表达,其配体能够激活同源受体,但 有丝分裂信号仅限于HGF/MET和EGFR。我们最近应用了短期击倒(KD) shRNA的HGF/MET或EGFR,并且证明两者都对肝脏再生有抑制作用, 一个信号无法完全补偿另一个信号,并且效果在范围上有所不同 复杂。 EGFR的KD之后,Erbb家族的其他成员的补偿性增加和 MET上调。在每种情况下,促凋亡途径的显着但没有致命的激活。 我们在大鼠中进一步扩展了这些研究,并进行了HGF/MET和EGFR的双KD 部分肝切除术(PHX)。结果是完全肝衰竭,大多数凋亡和坏死 肝细胞和肝实质的崩溃。当双KD是 没有PHX。拟议的研究将旨在确定导致肝衰竭的信号 假设许多参与肝脏再生(例如TNF和TGFB1)的细胞因子也可以作为 当EGFR和MET的有丝​​分裂信号无法 功能。除了实验研究外,我们还将分析激活的表达和状态 以上受体以及能够诱导人肝脏肝细胞死亡和肝衰竭的细胞因子 从暴发性肝坏死病例中获得的材料。最后,我们将评估 EGFR KD之后出现的补偿机制,并确定是否废除了这些机制 机制也能够本身导致肝衰竭。这些研究的结合可能使我们能够 理解导致大规模肝坏死的机制,因为早期的异常分离 参与肝脏再生的信号,并允许设计用于预防大规模的治疗干预措施 基于理性机械方案的肝坏死。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE K MICHALOPOULOS其他文献

GEORGE K MICHALOPOULOS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE K MICHALOPOULOS', 18)}}的其他基金

Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease
抑制 EGF 受体可预防和逆转非酒精性脂肪肝
  • 批准号:
    10117752
  • 财政年份:
    2021
  • 资助金额:
    $ 27.66万
  • 项目类别:
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease
抑制 EGF 受体可预防和逆转非酒精性脂肪肝
  • 批准号:
    10338190
  • 财政年份:
    2021
  • 资助金额:
    $ 27.66万
  • 项目类别:
FASEB SRC on Liver Biology: Fundamental Mechanisms and Translational Applications
FASEB SRC 肝脏生物学:基本机制和转化应用
  • 批准号:
    8720321
  • 财政年份:
    2014
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    8259209
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    7196476
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    6862635
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    8081865
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    7996306
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    8657817
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:
HGF and Signaling Pathways in Hepatic Tissue Assembly
HGF 和肝组织组装中的信号通路
  • 批准号:
    7022305
  • 财政年份:
    2004
  • 资助金额:
    $ 27.66万
  • 项目类别:

相似国自然基金

丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
  • 批准号:
    82360332
  • 批准年份:
    2023
  • 资助金额:
    31.00 万元
  • 项目类别:
    地区科学基金项目
利用可视可控hypocretin神经元凋亡的疾病模型进行发作性睡病发病机制研究
  • 批准号:
    81901346
  • 批准年份:
    2019
  • 资助金额:
    20.5 万元
  • 项目类别:
    青年科学基金项目
组织器官衰老致退行性演变多示踪剂全身动态PET显像研究
  • 批准号:
    91949121
  • 批准年份:
    2019
  • 资助金额:
    68.0 万元
  • 项目类别:
    重大研究计划
日粮AFB1在反刍动物肝脏中代谢激活和诱导肝细胞凋亡的分子机理研究
  • 批准号:
    31902187
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
阿司匹林丁香酚酯抗氧化应激致血管内皮细胞凋亡的分子机制
  • 批准号:
    31872518
  • 批准年份:
    2018
  • 资助金额:
    59.0 万元
  • 项目类别:
    面上项目

相似海外基金

The role of LPCAT3 in pathogenesis of diabetic cardiomyopathy
LPCAT3在糖尿病心肌病发病机制中的作用
  • 批准号:
    10867671
  • 财政年份:
    2023
  • 资助金额:
    $ 27.66万
  • 项目类别:
Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)
右美托咪定用于因新生儿脑病而接受降温的婴儿(DICE 试验)
  • 批准号:
    10571839
  • 财政年份:
    2022
  • 资助金额:
    $ 27.66万
  • 项目类别:
Dexmedetomidine Use in Infants undergoing Cooling due to Neonatal Encephalopathy (DICE trial)
右美托咪定用于因新生儿脑病而接受降温的婴儿(DICE 试验)
  • 批准号:
    10390861
  • 财政年份:
    2022
  • 资助金额:
    $ 27.66万
  • 项目类别:
Identifying novel targets for cardioprotection with non-traditional animal models
利用非传统动物模型确定心脏保护的新靶点
  • 批准号:
    10406111
  • 财政年份:
    2021
  • 资助金额:
    $ 27.66万
  • 项目类别:
Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA
使用脂质纳米颗粒封装的 TERT mRNA 进行短暂端粒延伸,增强肝脏再生能力,从而预防酒精性肝炎中的肝纤维化
  • 批准号:
    10082259
  • 财政年份:
    2020
  • 资助金额:
    $ 27.66万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了